Browsing: Ozempic
Drug regulators in Europe have found no evidence that popular diabetes and weight-loss drugs like Ozempic and Wegovy are linked…
GLP-1s Like Ozempic, Wegovy Don’t Substantially Increase Thyroid Cancer Risk, Study Suggests
Topline Popular diabetes and weight loss drugs like Ozempic and Wegovy, known as GLP-1 medications, were not found to cause…
Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5
Ozempic could be profitably produced for less than $5 a month even as maker Novo Nordisk A/S charges almost $1,000…
Ozempic maker Novo Nordisk has a new goal for its leadership team: Make sure no more than 10% of your staff are stressed
Workers today have much to be stressed out about; Geopolitical tensions are dominating their social media feeds, the cost of…
WeightWatchers, reeling from collapsing stock and Oprah’s departure in the age of Ozempic, vows to ‘prove the naysayers wrong’ and turn its fortunes around
The CEO at WW International, also known as WeightWatchers, told employees in a memo today that the company is on…
Ozempic Maker’s New Weight Loss Pill Beats Wegovy In Early Trial — What To Know About Novo Nordisk’s Amycretin
Topline Ozempic maker Novo Nordisk on Thursday teased a potential successor to its blockbuster weight loss drug Wegovy, the latest…
Goldman Sachs Says Weight Loss Drugs Are Good For Economy, But Obesity Prevention May Be Better
In the February 4, 1735 issue of the Pennsylvania Gazette, Benjamin Franklin wrote that “an ounce of prevention is worth…
Novo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out-of-pocket for them
The popularity of Novo Nordisk’s weight-loss drugs has been unprecedented and has shown no signs of fading. It’s clearly more…
Novo Nordisk hits $500bn market value, climbing closer to the $1tn club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
Novo Nordisk has shown few signs of slowing down since taking the pharmaceutical world by storm last year. Now, the…
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
North Carolina is cutting off coverage of anti-obesity medications for state employees, citing soaring costs and a lack of agreement…












